Fig. 2From: Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trialAdjusted survival probability by original study allocation of bezafibrate vs. placebo in patients with TG ≥200 mg/dL&. & Cox proportional hazard regression model adjusted for age, gender, hypertension, past MI, baseline glucose, BMI, NYHA ≥ II, HDL-C and diabetes statusBack to article page